Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 78.00 67,855 16:35:25
Bid Price Offer Price High Price Low Price Open Price
76.40 77.80 77.40 75.20 75.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.26 15.36 2.45 31.8 355
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:25 UT 1 78.00 GBX

Ekf Diagnostics (EKF) Latest News

More Ekf Diagnostics News
Ekf Diagnostics Investors    Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics (EKF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-18 15:35:2578.0010.78UT
2021-06-18 15:24:1676.40250191.00AT
2021-06-18 15:16:3676.40250191.00AT
2021-06-18 15:07:0276.76271208.03O
2021-06-18 14:22:0477.432,5721,991.56O
View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

Ekf Diagnostics Daily Update: Ekf Diagnostics Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 78p.
Ekf Diagnostics Holdings Plc has a 4 week average price of 72p and a 12 week average price of 64p.
The 1 year high share price is 83p while the 1 year low share price is currently 41p.
There are currently 454,993,227 shares in issue and the average daily traded volume is 274,092 shares. The market capitalisation of Ekf Diagnostics Holdings Plc is £354,894,717.06.
btgman: I want to look a little further at ekf and the Trellus scenario if I may. Ekf use ekf cash to invest in Trellus for the benefit of EKF shareholders. So let's look at £100k investment in EKF say 150,000 shares. This gives 9230 specie shares @65p profit £6k Follow on £100k application in restricted offer assuming 6.5% £6500 of shares received at 65p profit £4062.50 So £10,650 profit. To make £10,650 in the ipo you would need to invest circa £17k Ekf shareholders held 30% of Trellus post raise and potentially receive 3.2% of the ipo. I really do wonder where the benefit really goes to? Perhaps someone could post who got what and how this compares to the EKF shareholders. Going forward the attraction of the specie dividend exists but it is not what I expected it to be. EKF is a solid company with great prospects but the events of the ipo has taken the shine off it morally for me.I get many companies don't allow shareholders to take part but 3.2% of the ipo is too skinny. With a fairer distribution at the ipo it is easy to rectify but Trellus waa the one for me and paying 65% more doesn't sit well as an EKF Trellus holder pre float AIMHO GLA BTG
mirandaj: From December - the facts: On 11 December 2020 the board of EKF (the "Board") convened and declared a dividend in specie of shares in Trellus to trustees, to be held on trust for the Company's shareholders (the "Dividend"). EKF's investment in Trellus comprises 27,999,999 A Shares of £0.0001 each and 1 golden share of £0.0001 (the "Golden Share"). The Golden Share is the voting share in the capital of Trellus and will be retained by the Company. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited ("Broadway"), at which time an 'omnibus' share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: · 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or · if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the "Lock-up Period"). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. The A Shares and the Golden Share will, on the earlier of the admission to trading of Trellus on AIM (or another recognised stock exchange) and two years from the date that the Dividend is settled, automatically convert into ordinary shares in Trellus ("Ordinary Shares") on the basis of one Ordinary Share for each A Share or Golden Share held. If Trellus is admitted to trading on AIM (or another recognised stock exchange), the Lock-up Period will continue to apply to the converted Ordinary Shares. All converted Ordinary Shares will rank equally in all respects with all other Ordinary Shares including in respect of voting and dividend rights. The legal title to the Dividend Shares will be held by Broadway as trustee, during the Lock-Up Period. If the A Shares are converted into Ordinary Shares during the Lock-up Period, Broadway will request that Trellus' registrar seeks the voting instructions of the Relevant EKF Shareholders in relation to any shareholder resolution of Trellus and will vote those Dividend Shares in accordance with such instructions as it receives . At the end of the Lock-up Period, Broadway will execute stock transfer forms to transfer the Dividend Shares to the Relevant EKF Shareholders based on a schedule provided by the Company's registrar. Relevant EKF Shareholders will receive a letter informing them of their beneficial holdings of Dividend Shares shortly after the transfer of the Dividend Shares to Broadway. Following the Lock-up Period, Relevant EKF Shareholders will receive individual certificates in respect of their Dividend Shares. The anticipated timetable for the Dividend is: EKF ordinary shares marked as ex rights Start of trading on 16 December 2020 Record date for the distribution of the Dividend Close of business on 17 December 2020 Transfer of shares in Trellus to Broadway as trustee 18 December 2020 The undertaking in relation to Broadway acting as legal holder of the Dividend Shares can be accessed via the investor section of the Company's website.
wan: I decided I would remind myself what Chris Mills said in an interview on the 17th November 2020 regarding EKF when the share price was 64p. In short, there were a number of elements he regarded as being in the price for free at 64p, albeit he did state at some point they would have to sell some shares, as EKF would be too big a percentage of their portfolio, "but it sure ain't at this price" (64p). He also said EKF had "life way beyond COVID". Interview (EKF at 15mins 40 seconds in) hTTps:// So, as discussed on here, we probably know why Chris Mills sold some at 80p, but given his remarks regarding the price at 64p, investors will no doubt be wondering where the floor is. So, it will thus be interesting to see if we are there yet, but it is perhaps worth recalling that the directors are incentivised in the event that the Company is acquired by a third party. However, clearly Chris Mills expects more that 64p for their EKF shares, believing there are elements included in the price for free and plenty of growth to go for too beyond COVID, which apparently we will be updated on. An exit is not something I would normally highlight, nor indeed promote ("not at this price"), but there is currently a lot of M&A in our sector. To be clear, an exit is currently not what I am wishing for though, but I do wonder whether some form of change is afoot. Currently, I see more reasons to buy than sell, but investors should of course make up their own minds when making investment decisions etc.
wan: Based on the most recent trading update & expansion of supply agreement, which I believe to be conservative, what are we, or indeed the Sunday Times journalist, missing from what we have been guided? - EKF Diagnostics Holdings PLC Trading update & Expansion of supply agreement 30/03/2021 Further to the announcement on 12 January 2021 , trading in the first quarter was materially ahead of management expectations. With subsequent orders under this expanded global contract expected to make a considerable contribution throughout the current financial year and beyond, the Board is confident that trading for the year ending 31 December 2021 will be significantly ahead of already upgraded management expectations. Julian Baines, CEO of EKF, said: "We are delighted to continue our relationship with our partner in the private sector and support their global staff testing initiative with the expansion of our supply agreement for collection kits. The contract has gone from covering the UK to supporting our partner's global staff testing programme. We expect this partnership to contribute materially to our 2021 performance and are confident in delivering results significantly ahead of current management forecasts which were most recently upgraded in January this year." Full release - hTTps:// Subsequently N-1 Singer analyst Chris Glasper upgraded his forecast for December 2021 revenues to £64 million and adjusted pre-tax profit to £15.5 million. From the recent Presentation - 2021 Outlook The Board is confident that trading for the year ending 31 December 2021 will be significantly ahead of already upgraded management expectations throughout 2021 • 30 March 2021 announced the signing of a multi-million dollar global supply contract with a private sector partner • Core business experiencing a strong recovery, particularly in the US McKesson OEM of DiaSpect Tm expected to return to pre-pandemic sales expectations • Customer base intact but was impacted by closure of physicians’ offices to medical sales representatives throughout 2020 • Placement of analysers into setting expected to return to 2020 levels (c. 100 per month) during 2021 Continued demand for PrimeStore MTM tubes and bulk medium • £2.49m of orders to Ireland in Q1 (versus £5.2m in 2020) • £3m+ of orders in-house from Concepta, Oncologica and PHE Manchester Orders of PBS (phosphate-buffered saline) to exceed £2.4m in Q1 • Two-year global supply contract with a major international brand customer for regular staff testing and home-use • Manufactured at sites in the US, UK and Germany Trellus Health flotation expected in H1 2021 to generate further value for holders hTTps:// Whilst I am sure there will be a combination of both headwinds and tailwinds, EKF's management were confident enough to upgrade the whole year (and adding materially beyond 2021). Not to mention that parts of the globe, where I assume said private sector partner also has staff, are not as fortunate as we are in terms of vaccine availability/roll-outs and low infection rates, hence the likes of Amazon is expanding their testing sites 'globally' - Amazon’s COVID-19 testing lab processes more than 1 million tests for front-line employees February 11, 2021 “Our team came together with a mission to rapidly build an in-house COVID-19 testing lab because we knew it was a final step, on top of all our onsite COVID-19 precautions, to ensure the health and safety of our front-line employees,” said Cem Sibay, Vice President, Amazon. “We built this lab to scale so that we can offer regular testing to all Amazon front-line employees. Over 500,000 employees have already been voluntarily tested and we are continuing to expand to over a thousand COVID-19 testing sites globally.” hTTps:// I would also suggest that testing will remain a critical factor/requirement for the likes of Amazon as we enter the flu seasons (is it flu or COVID?). And beyond COVID-19 (hopefully and eventually) Amazon's testing infrastructure and capabilities will no doubt be put to further good use.
travestor: Started so well, heyho i was toying with a top up, might just get a bargain now: Apply the sniff test to this Covid winner Sabah Meddings Sunday May 09 2021, 12.01am BST, The Sunday Times It has 1.3 million staff, warehouses worldwide and a market value of $1.7 trillion. Can you name this company? You will not find the answer in March’s stock exchange announcement from EKF Diagnostics, in which it boasted about a multimillion-dollar contract with a mystery global partner in the private sector, sending its share price over 5 per cent. However, City speculation suggests that the AIM-listed EKF has scored a two-year deal with Amazon. EKF is not at liberty to confirm, but this deal is expected to be worth many millions. Not bad going for a company that was a penny stock five years ago. EKF, led by chairman Christopher Mills, a small-cap veteran who made his name at JO Hambro in the 1990s, specialises in “point of care” tests where physicians can find out in real time whether patients are suffering from conditions such as anaemia, diabetes or sepsis. It is also a “Covid stock”. EKF makes sample collection kits that keep the virus “inactivated” (meaning it is no longer able to infect anyone) in the collection tube — avoiding contamination while preserving the crucial RNA macromolecule. EKF supplies these testing kits to Public Health England and the Irish government, along with private customers. Shares in the company have risen more than 220 per cent since the middle of March last year, closing on Friday at 70.40p and giving EKF a value of £320.3 million. So far, so good. However, the City was spooked slightly last month when Mills, 68, sold almost four million shares at 80p each, cutting his stake from 29.7 per cent to 29 per cent (he first bought in at 9p). The stock has drifted 13 per cent since then. Sources suggest that Mills has a long-term plan to diversify his portfolio, and that he is likely to sell more if the good news continues. Elsewhere, the longevity of EKF’s uplift is in question. Covid-related sales accounted for 40 per cent of last year’s revenues of £65.3m — up 45 per cent — but beyond Covid, sales have fallen short. EKF’s clinical chemistry, diabetes and haematology divisions all declined as patients stayed away from doctors — reducing demand for its screening products. SPONSORED EKF has more than £30 million of cash and investments. It is launching a product that can test rapidly for sepsis, which kills 48,000 a year in the UK, and it is expected that it will soon launch a plan to double core earnings over the next three to four years. The question is whether its share price will get a dose of reality once the demand for testing is over. For now, investors would be wise to follow Mills and take profits.
wan: Quite often, Director share purchases and sales are more about timing and demand, than the underlying business or its future prospects etc. To perhaps highlight this fact, the following transactions by Adam Reynolds appears to demonstrate that director selling does not always align with poor business prospects, and neither was it useful as an indicator/predictor of poor share price performance - 09 November 2018, Adam Reynolds, Non-executive Director, sold 1,250,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares")at a price of 27.25 pence per share hTTps:// 28 May 2019, Adam Reynolds, Non-executive Director, sold 400,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at a price a 33 pence per share hTTps:// One might even conclude that the same positive theme, in terms of share price performance, could apply to yesterdays transaction, time will tell!
wan: To perhaps better frame the above article in terms of how that might present opportunity to EKF, recently I stated the following - During the recent Presentation meeting, Julian Baines (CEO) described EKF as supplying the picks & shovels to the Covid opportunity and described it as making the 'real' money. I also took note of him saying just after that comment, that EKF will/would/could (not sure which as I could not take notes quickly enough) become one of the world's major manufacturers of test kits. I think he was also referring to the manufacture/assembly of home-use testing kits, and I assume such test kits being used beyond that of testing just the employees of the recently announced private sector partner (but again, those 1m + employees should not be underestimated, in terms of volumes, and perhaps not just for Coronavirus testing). (END) And Hastings also covered this aspect in his CEO interview/update (excerpt follows)- He adds that the world was already going down that route before the onset of Covid and that has now accelerated, where given that this customer has such a huge distribution network and its own PCR lab it seems a natural progression for it move into home diagnostics. Going on the CEO adds that EKF has been more than just a manufacturing partner as it has supported the customer through the tough regulatory hurdles as they have progressed. “We had the expertise in this area to support and assist them and as a result we have become a very close- knit partner. But, they haven’t invested millions in their own PCR lab to just stop when Covid quietens down, they are fully intended to move into other areas”. Beyond this significant customer and the undoubted opportunities for EKF, I touch upon its wider position across manufacturing test kits. The CEO says “there are a number of opportunities in front of us as companies have discovered that there are very few partners that can actually do the kitting”. There are, he says, regulatory issues and quality that others cannot overcome which puts EKF in a very strong position for further progress across this area. “In PrimeStore I see a huge opportunity as you have got to remember that it kills the pathogen, so I can see it being used in areas such as malaria or ebola and others. As one example Public Health England have already got it in their workflow for pathogens not just Covid, so we see some really good opportunities ahead”. Martins full article - hxxps://
wan: The following has been on my mind for a while and provides further food for thought - Lateral flow tests are dependant upon a number of factors in terms of performance, not least by the preparation/make up of the buffer solution. This is quite often in the form of a Phosphate Buffer Saline (PBS), which is used for the sample dilution (and of course sample collection/protection). So, the buffer solution and composition represents a critical element of the test, which can also affect the accuracy of the test. Recall that EKF has commenced production of PBS for collection kits - Additional production lines for Phosphate Buffered Saline (PBS) established Q1 2021 at Boerne, South Bend, Barleben and Cardiff sites Orders of PBS (phosphate-buffered saline) to exceed £2.4m in Q1 • Two-year global supply contract with a major international brand customer for regular staff testing and home-use • Manufactured at sites in the US, UK and Germany hTTps:// For reference - 30 March 2021 Trading update & Significant expansion of supply agreement for COVID-19 sample collection kits Private sector partnership with EKF for global staff testing programme Under this new multiyear global supply contract, EKF will now support its partner's world-wide staff testing initiative, with orders being fulfilled from EKF's production sites in the UK, Germany and the United States. The Company expects orders from the expanded agreement to reflect EKF's increased contribution to their partner's global testing programme, and therefore this agreement is expected to facilitate future orders which will contribute materially to 2021 performance and beyond. The contract has an initial term of two years after which it renews automatically on a monthly basis. Further to the announcement on 12 January 2021 , trading in the first quarter was materially ahead of management expectations. With subsequent orders under this expanded global contract expected to make a considerable contribution throughout the current financial year and beyond, the Board is confident that trading for the year ending 31 December 2021 will be significantly ahead of already upgraded management expectations. hTTps:// There is obviously differences between PBS for sample collection/collection kits and that for a lateral flow test, but I had been wondering about the difference in terms of the manufacturing processes for each, which don't seem miles apart from my layman perspective, especially as the required lab facilities in terms of sterile environment/product are in place. It would certainly fit well with the supplying of the picks & shovels terminology. Anyway, as I said at the beginning, it's only food for thought at this stage.
wan: Nurdin...Whilst Mr Stewart for the Daily Mail clearly recognises the history of success from the management team over some years, he makes no reference to that in any detail. With perhaps good reason if you are hoping to buy in at a cheaper price! As I said in several recent posts, there are indeed a number of reasons beyond the metrics (that indicate a full price) to be bullish on EKF. Some of these are well covered in Hastings write-up. Furthermore, looking beyond the financial metrics that JUS is obviously relying on or indeed implying, how does one value the agreement and relationship with Mount Sinai? This agreement and relationship provides EKF with advanced access to innovative commercial opportunities and presents significant opportunity for EKF to collaborate on ground breaking medical technologies that can be spun off and proceed down the IPO route. This has already resulted in shareholders benefiting from owning shares via a dividend in-specie in the spin off, Renalytix (price at IPO £1.21 per share, share price now circa £10) and now Verici (if you kept your Renalytix shares with a current share price of circa 60p and in which EKF have received 2,677,981 shares), with Trellus Health next in line for an IPO. However, the management are aiming to replicate this process further with at least one investment and IPO per year. Not two a penny, as these things take time, but if you were only focused on certain financial metrics (as perhaps JUS implies), then you wouldn't have been invested in EKF any earlier either to have benefited from what is arguably difficult to measure. And I would suggest that Mr Stewart has likewise been unable to measure this aspect either.........however, arguably it must surely be worth at least some form of premium to get such exposure? The managements track record in terms of delivery (not just the IPO's) is very encouraging indeed, and JUS has at least 'tentatively' recognised that fact! And this is before I get into EKF's close-knit relationship with their new private sector partner (believed to be Amazon) and who's logistical expertise and ambitions extend 'far beyond' testing just their own employees (and with over 1 million employees this on its own should not be underestimated).
wan: It looks like JUSTIN URQUHART STEWART FOR THE DAILY MAIL, likes EKF, but he hopes he can buy it cheaper, but he clearly does not fully appreciate what else is under EKF's bonnet (nor appreciates who EKF's private partner is and how that relationship might evolve, or perhaps even hoping it's not actually revealed anytime soon). Time will tell, but he might do well to read Hastings excellent and most recent coverage - EKF - A HEALTHY INVESTMENT - 09/03/21 Whilst the huge level of success from its PrimeStore offering has been the key driver of EKF’s share price over the last year, there continues to be much more on offer here. Full article - hTTps:// The Daily Mail piece - MR MONEY MAKER: EKF Diagnostics has the kit to give your portfolio a shot in the arm By JUSTIN URQUHART STEWART FOR THE DAILY MAIL PUBLISHED: 21:50, 9 April 2021 Any suggestions? So I like to look for history of success from the team over some years. EKF Diagnostics certainly has this, but the price is quite full. I would prefer to keep it on the watch list and wait for a pullback, which will be coming in the not too distant future. Full story - hTTps:// As I said previously, there are indeed other reasons to be bullish on EKF (more of which later), and thus in my view there will likely be plenty of investors in the wings hoping to buy before upgrades (given the current broker conservatism), or on any weakness. JUS is clearly one one of those, and to a degree, talking it down to help achieve that. Importantly though, and as a consequence, any meaningful weakness (if it materialises) might be very short lived!
Ekf Diagnostics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 14:33:52